NKG2D CAR-NK & r/rAML - Trial NCT05734898

Name: Clinical Trial NCT05734898
Creator: Zhejiang University
Keywords: AML, NKG2D CAR-NK, biological, clinical trial, China

Access comprehensive clinical trial information for NCT05734898 through Pure Global AI's free database. This phase not specified trial is sponsored by Zhejiang University and is currently Recruiting. The study focuses on AML. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database

840K+ Trials

NCT05734898

Recruiting

biological

Trial Details

ClinicalTrials.gov • NCT05734898

View on ClinicalTrials.gov

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

NKG2D CAR-NK & r/rAML

NKG2D CAR-NK Cell Therapy for the Treatment of Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Study Focus

Disease/Condition

AML

Drug/Device/Intervention

NKG2D CAR-NK

Study Type

Interventional

Intervention Type

biological

Sponsor & Location

Primary Sponsor

Zhejiang University

Location

Hangzhou,Hangzhou, China

Timeline & Enrollment

Phase

N/A

Start Date

Mar 01, 2023

End Date

Sep 01, 2024

Enrollment

30 participants

Primary Outcome

DLT,MTD

Summary

This trial will explore the maximum tolerated dose（MTD）of NKG2D CAR-NK cells in the treatment of relapsed or/and refractory AML in a dose-escalation manner, and observe the clinical safety and efficacy.

ICD-10 Classifications

Acute myeloblastic leukaemia [AML]

Data Source

Registry

ClinicalTrials.gov

Trial ID

NCT05734898

Type

Non-Device Trial